ARS Pharmaceuticals, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On March 11, 2022, Thilo Schroeder, Ph.D. informed Silverback Therapeutics, Inc. (the “Company”) that he will not stand for re-election as a member of the Company’s board of directors when his term as a Class II director expires at the Company’s 2022 annual meeting of stockholders and on March 14, 2022, Dr. Schroeder resigned as a member of the audit committee of the board of directors of the Company (the “Audit Committee”) to focus on other endeavors.
Extracted from this filing and checked against the source text.
Thilo Schroeder departed as Director at ARS Pharmaceuticals, Inc..
On March 11, 2022, Thilo Schroeder, Ph.D. informed Silverback Therapeutics, Inc. (the “Company”) that he will not stand for re-election as a member of the Company’s board of directors when his term as a Class II director expires at the Company’s 2022 annual meeting of stockholders and on March 14, 2022, Dr. Schroeder resigned as a member of the audit committee of the board of directors of the Company (the “Audit Committee”) to focus on other endeavors.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.